Perglim-M2 (Glimepiride + Metformin)

Glimepiride + Metformin is an oral antidiabetic combination therapy used to manage type 2 diabetes mellitus when diet, exercise, or single-drug therapy alone are insufficient.

• Glimepiride (a sulfonylurea) works by stimulating the pancreas to release more insulin.
• Metformin (a biguanide) reduces hepatic glucose production and improves peripheral insulin sensitivity.

Together, they provide a synergistic effect, improving blood sugar control and reducing the risk of long-term diabetes-related complications.

Main Uses

• Management of type 2 diabetes mellitus
• Helps lower fasting and postprandial blood glucose levels
• Reduces risk of microvascular and macrovascular complications of diabetes
• Beneficial for patients not controlled on metformin or glimepiride alone
• Improves glycemic control in overweight or obese patients

Contraindications

This combination should be avoided in patients with:

• Type 1 diabetes mellitus
• Diabetic ketoacidosis (DKA) with or without coma
• Severe renal impairment (eGFR <30 mL/min/1.73 m²)
• Severe hepatic impairment
• Hypersensitivity to glimepiride, metformin, sulfonylureas, or sulfonamides
• Conditions predisposing to hypoxia (cardiac/respiratory failure, recent myocardial infarction, shock)
• Alcohol abuse (increases risk of lactic acidosis with metformin)
• Pregnancy and lactation (unless specifically recommended by a physician)

Dosage: The dosage of this medicine depends on the prescription and instruction given by the doctor.

Precautions: Do not take this medicine without any medical consultation with your doctor.